News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Apalutamide for castration-resistant prostate cancer yields real-world results
25 Mar 2022
Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) who have been initiated on apalutamide in a real-world setting appear to show prostate-specific antigen (PSA) response that is strong and consistent with that reported in clinical trials, as reported in a study.
25 Mar 2022








